# Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis

> **NCT01119339** · PHASE2 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 20 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** LAS 41004
- **DRUG:** LAS 41004
- **DRUG:** LAS 41004
- **DRUG:** LAS 41004
- **DRUG:** LAS 41004
- **DRUG:** LAS 41004 dosage 6
- **DRUG:** Placebo
- **DRUG:** Reference

## Key facts

- **NCT ID:** NCT01119339
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2015-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01119339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01119339, "Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01119339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*